A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer
โ Scribed by Smith, David B.; Howell, Anthony
- Book ID
- 122807853
- Publisher
- Elsevier Science
- Year
- 1989
- Weight
- 279 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0277-5379
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s
Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to th